3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Testicular Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms, Unknown Primary
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Death
1
Colonic Neoplasms
1
Interventions
Etoposide
19
Carboplatin
19
Ifosfamide
16
Filgrastim
16
Peripheral Blood Stem Cell Transplantation
13
Paclitaxel
13
Cisplatin
12
Cyclophosphamide
10
Thiotepa
7
Therapeutics
5
Radiotherapy
5
Melphalan
5
Busulfan
5
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Flow Cytometry
4
pegfilgrastim
3
etoposide phosphate
3
Surveys and Questionnaires
3
Psychiatric Rehabilitation
3
Methylprednisolone
3
Methods
3
Immunologic Techniques
3
Granulocyte Colony-Stimulating Factor
3
Epirubicin
3
Dexamethasone
3
Blood Specimen Collection
3
Bleomycin
3
tremelimumab
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Testicular Neoplasms
×
erythromycin propionate-N-acetylcysteinate
×
Clear all
NCT02966509
2018-10-31
EPAC
Stanford University
Phase NA
Completed
213 enrolled
20 charts